Zobrazeno 1 - 9
of 9
pro vyhledávání: '"M B, Tombes"'
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 4(3)
A Phase Ib trial of bryostatin 1, a macrocyclic lactone and protein kinase C (PKC) activator, was conducted in patients with refractory nonhematological malignancies with the primary goal of determining whether down-regulation of peripheral blood mon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fab429e0390da0cdf5b2580d3734d015
https://pubmed.ncbi.nlm.nih.gov/9533528
https://pubmed.ncbi.nlm.nih.gov/9533528
Autor:
M B, Tombes
Publikováno v:
ONS news. 11(8)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::01e0cb4142d6bca7a67ca6d6e4a80e9c
https://pubmed.ncbi.nlm.nih.gov/8932202
https://pubmed.ncbi.nlm.nih.gov/8932202
Autor:
M B, Tombes, B, Gallucci
Publikováno v:
Nursing research. 42(6)
Oral mucosal effects of hydrogen peroxide mouth rinses were investigated in normal volunteers. Following a 2-week control period, 35 subjects were randomly assigned to rinse with either normal saline, 1/4-strength hydrogen peroxide (0.75%), or 1/2-st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6c2bc91309276f5befabe459ebe0043d
https://pubmed.ncbi.nlm.nih.gov/8247815
https://pubmed.ncbi.nlm.nih.gov/8247815
Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor
Autor:
J H, Schiller, P L, Witt, B, Storer, D, Alberti, M B, Tombes, R, Arzoomanian, R R, Brown, R A, Proctor, S D, Voss, D R, Spriggs
Publikováno v:
Cancer. 69(2)
Tumor necrosis factor (TNF) and gamma-interferon (gamma-IFN) are cytokines with synergistic biologic and antiproliferative effects in vitro and in mouse models. The biologic effects of the combination of TNF and gamma-IFN, however, have not been stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4a7371133a94bdb340c3772efe953db8
https://pubmed.ncbi.nlm.nih.gov/1728387
https://pubmed.ncbi.nlm.nih.gov/1728387
Autor:
J H, Schiller, B E, Storer, P L, Witt, D, Alberti, M B, Tombes, R, Arzoomanian, R A, Proctor, D, McCarthy, R R, Brown, S D, Voss
Publikováno v:
Cancer research. 51(6)
Tumor necrosis factor (TNF) is a cytokine with pleiotropic biological and antitumor effects in vitro and in mouse models. The immunological effects of the molecule as a single agent, however, have not been well studied clinically. We conducted a Phas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fb90d1df6631b1ccc65101b1a26caa21
https://pubmed.ncbi.nlm.nih.gov/1998956
https://pubmed.ncbi.nlm.nih.gov/1998956
Publikováno v:
Cancer research. 51(4)
A phase I trial of fazarabine (ara-AC, 1-beta-D-arabinofuranosyl-5-azacytosine, NSC 281272) administered as a 24-h continuous infusion was performed in 24 adults with solid tumor malignancies. The majority of patients had received prior marrow-suppre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::89bb14e5a6bf23e4b989653c61518bfb
https://pubmed.ncbi.nlm.nih.gov/1705165
https://pubmed.ncbi.nlm.nih.gov/1705165
Autor:
H, Bailey, R T, Mulcahy, K D, Tutsch, J M, Rozental, D, Alberti, R Z, Arzoomanian, M B, Tombes, D L, Trump, G, Wilding
Publikováno v:
Cancer research. 51(4)
SR-2508, a less lipophilic ane neurotoxic analogue of the nitroimidazole, misonidazole, has exhibited significant chemosensitization properties in preclinical studies with alkylating agents. A phase I trial was carried out to assess toxicity and poss
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0109439f10bf61055bc1788a25d21e23
https://pubmed.ncbi.nlm.nih.gov/1825475
https://pubmed.ncbi.nlm.nih.gov/1825475
Autor:
S C, Remick, J L, Grem, P H, Fischer, K D, Tutsch, D B, Alberti, L M, Nieting, M B, Tombes, J, Bruggink, J K, Willson, D L, Trump
Publikováno v:
Cancer research. 50(9)
Forty-seven patients with advanced malignancies were treated with a concurrent 72-h continuous infusion of 5-fluorouracil (FUra) and dipyridamole. The FUra dose was escalated over the dose range of 185 to 3600 mg/m2/day for 3 days. Dipyridamole was a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8b1d68f2740570e7258329d9b17fe16c
https://pubmed.ncbi.nlm.nih.gov/2328492
https://pubmed.ncbi.nlm.nih.gov/2328492